Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PRECISION BIOSCIENCES INCDTIL · Entity 6284 | Director · President and CEO | August 21, 2020 | June 11, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PRECISION BIOSCIENCES INC
Report date August 21, 2020 · Filed June 11, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.83 · Expires 2030-08-20 | IndirectBy Spouse | 1,743 |
Reported balance
After 2020-08-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-08-21 · Grant · Acquired 1,743 · Balance 1,743 F1: The option vests as to 25% of the underlying shares on April 1, 2021 and thereafter in twelve equal installments at the end of each three-month period over the 36 months following such date. F2: Employee Stock Option is held by Chelsea Lynam Kane, the spouse of the reporting person. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 25% of the underlying shares on April 1, 2021 and thereafter in twelve equal installments at the end of each three-month period over the 36 months following such date.
F2: Employee Stock Option is held by Chelsea Lynam Kane, the spouse of the reporting person. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 08, 2020 Filed Jun 10, 2020 21:00 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantEmployee Stock Option (Right to Buy) · Derivative | 202,391 | $0.00 Strike: $8.21 | $0.00 |
DisclosureSEC source: 0001209191-20-035591 · doc4.xml · derivative · entry 1 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,391 Underlying: Common Stock · 202,391 shares Expires 2030-06-07 F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares on April 1, 2021 and vests in equal installments at the end of each successive three-month period over the 36 months following such date. Read SEC document |
| September 23, 2019 Filed Sep 25, 2019 20:23 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantEmployee Stock Option (Right to Buy) · Derivative | 262,252 | $0.00 Strike: $9.46 | $0.00 |
DisclosureSEC source: 0001209191-19-050699 · doc4.xml · derivative · entry 4 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,252 Underlying: Common Stock · 262,252 shares Expires 2029-09-22 F3 · derivative.exercise_date: The option vests as to 25% of the underlying shares on April 1, 2020 and vests in equal installments at the end of each successive three-month period over the 36 months following such date. Read SEC document |
| September 23, 2019 Filed Sep 25, 2019 20:23 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001209191-19-050699 · doc4.xml · derivative · entry 3 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,422 Underlying: Common Stock · 10,000 shares Expires 2027-03-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested as to 25% of the underlying shares on March 24, 2018 and vests in equal installments at the end of each successive three-month period over the 36 months following such date. Read SEC document |
| September 23, 2019 Filed Sep 25, 2019 20:23 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 10,000 | $1.18 | $11,800.00 |
DisclosureSEC source: 0001209191-19-050699 · doc4.xml · nonDerivative · entry 1 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,812,427 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.